Menu Search
Equities

Alkem Laboratories Ltd

ALKEM:NSI

Alkem Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)5,583.35
  • Today's Change-23.40 / -0.42%
  • Shares traded108.53k
  • 1 Year change+22.98%
  • Beta0.6204
Data delayed at least 15 minutes, as of Nov 22 2024 10:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform4
Hold6
Sell3
Strong Sell2

Share price forecast in INR

The 17 analysts offering 12 month price targets for Alkem Laboratories Ltd have a median target of 6,053.00, with a high estimate of 7,225.00 and a low estimate of 4,330.00. The median estimate represents a 7.96% increase from the last price of 5,606.75.
High28.9%7,225.00
Med8.0%6,053.00
Low-22.8%4,330.00

Dividends

In 2024, Alkem Laboratories Ltd reported a dividend of 40.00 INR, which represents a 60.00% increase over last year. The 15 analysts covering the company expect dividends of 48.31 INR for the upcoming fiscal year, an increase of 20.78%.
Div growth (TTM)60.00%
More ▼

Earnings history & estimates in INR

On Nov 13, 2024, Alkem Laboratories Ltd reported 2nd quarter 2025 earnings of 57.60 per share.
The next earnings announcement is expected on Feb 07, 2025.
Average growth rate+12.94%
Alkem Laboratories Ltd reported annual 2024 earnings of 160.35 per share on May 29, 2024.
Average growth rate+21.81%
More ▼

Revenue history & estimates in INR

Alkem Laboratories Limited had 2nd quarter 2025 revenues of 34.15bn. This missed the 36.49bn consensus estimate of the 11 analysts following the company. This was 15.06% above the prior year's 2nd quarter results.
Average growth rate+0.21%
Alkem Laboratories Limited had revenues for the full year 2024 of 126.68bn. This was 9.21% above the prior year's results.
Average growth rate+11.12%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.